MicroRNA profile in stage I clear cell renal cell carcinoma predicts progression to metastatic disease.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
10 2020
Historique:
received: 23 03 2020
revised: 29 04 2020
accepted: 09 05 2020
pubmed: 15 6 2020
medline: 29 6 2021
entrez: 15 6 2020
Statut: ppublish

Résumé

This study sought to identify microRNA (miRNA) profiles of small, pathologically confirmed stage 1 clear cell renal cell carcinoma (ccRCC) tumors that are associated with progression to metachronous metastatic disease. Fifty-five pathologic stage 1 ccRCC tumors ≤5cm, from 2 institutions, were examined in a miRNA screening, followed by a validation study. For the screening phase 752 miRNA were evaluated on each sample to identify those with differential expression between tumors that subsequently did (n = 10) or did not (n = 10) progress to metastatic disease. For the validation, 35 additional samples (20 nonprogressors and 15 with distant progression) were utilized to investigate 20 miRNA to determine if a miRNA panel could differentiate aggressive tumors: associations of miRNA expression with cancer specific survival was also investigated. In the screening analysis, 35 miRNA were differentially expressed (P < 0.05, FDR < 0.1) between the groups. In the validation, 11 miRNA were confirmed to have differential expression. The miRNA -10a-5p, -23b-3p, and -26a-5p differentiated nonprogressive and distant progressive disease with a sensitivity of 73.3% and a specificity of 85% (AUC=0.893). In addition, levels of miR-30a-3p and -145-5p were identified as independent prognostic factors of cancer specific survival. This investigation identified miRNA biomarkers that may differentiate between non-progressive ccRCC tumors and those that progress to metastatic disease in this group of stage I tumors. The miRNA profiles determined in this study have the potential to identify patients with small renal masses who are likely to have progressive ccRCC. Such information may be valuable to incorporate into predictive models.

Identifiants

pubmed: 32534961
pii: S1078-1439(20)30210-6
doi: 10.1016/j.urolonc.2020.05.006
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
MicroRNAs 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

799.e11-799.e22

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Matthew J Moynihan (MJ)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA.

Travis B Sullivan (TB)

Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA.

Eric Burks (E)

Department of Pathology, Lahey Hospital & Medical Center, Burlington, MA.

Jared Schober (J)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA.

Marc Calabrese (M)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA.

Ariel Fredrick (A)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA.

Thomas Kalantzakos (T)

Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA.

Joshua Warrick (J)

Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, PA.

David Canes (D)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA.

Jay D Raman (JD)

Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA.

Kimberly Rieger-Christ (K)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA; Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA. Electronic address: Kimberly.R.Christ@lahey.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH